neuroimmune

Neurimmune is a biopharmaceutical company focused on translating human immune memory into antibody therapeutics for neurodegenerative and protein aggregation diseases. Its pipeline includes drug candidates for conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), fronto-temporal dementia, cardiomyopathy, and type 2 diabetes. The company utilizes its proprietary Reverse Translational Medicine™ technology to develop antibodies with high affinity, target selectivity, and low immunogenicity, primarily targeting central nervous system diseases and related protein aggregation disorders

neuroimmune was discovered on July 29th 2024 and it currently has a search volume of 6.6K with a growth of +600%.